Xbrane Biopharma AB (XBRANE) — Capital Reinvestment Ratio

Latest as of December 2024: 0.18x

Xbrane Biopharma AB (XBRANE) has a Capital Reinvestment Ratio of 0.18x as of December 2024, meaning it reinvests 0% of its operating cash flow (Skr93.91 Million) in capital expenditures (Skr17.30 Million). Check XBRANE intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.18x
Capex / Operating Cash Flow

Operating Cash Flow

Skr93.91 Million
SEK

Capital Expenditures

Skr17.30 Million
SEK

Data as of

Dec 2024
Most recent filing

Xbrane Biopharma AB Capital Reinvestment Ratio (2018–2018)

This chart tracks Xbrane Biopharma AB's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Xbrane Biopharma AB cash flow conversion.

Annual Capital Reinvestment Ratio for Xbrane Biopharma AB (2018–2018)

Year-by-year Capital Reinvestment Ratio for Xbrane Biopharma AB from 2018 to 2018. See Xbrane Biopharma AB (XBRANE) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (SEK) Capital Expenditures YoY Change
2018 0.03x Skr46.71 Million Skr1.60 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow